Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping

Cytogenetics and Cell Genetics

Volumn 87, Issue 3-4, 1999, Pages 225-232

  Pan, Yi ^a   Kytola S ^a   Farnebo, F ^a   Wang, N ^a   Lui, W O ^a   Nupponen, N ^b   Isola, J ^a,b   Visakorpi, T ^b   Bergerheim, U S R ^a   Larsson, C ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CHROMOSOME 1; CHROMOSOME 10; CHROMOSOME 15; CHROMOSOME 16; CHROMOSOME 2; CHROMOSOME 4; CHROMOSOME 6; CHROMOSOME BREAKAGE; CHROMOSOME TRANSLOCATION; COMPARATIVE GENOMIC HYBRIDIZATION; DNA PROBE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; KARYOTYPING; MALE; PRIORITY JOURNAL; PROSTATE CANCER; STRUCTURAL CHROMOSOME ABERRATION;

EID: 0343067144     PISSN: 03010171     EISSN: None     Source Type: Journal    
DOI: 10.1159/000015432     Document Type: Article

References (38)

1. Bergerheim US, Kunimi K, Collins VP, Ekman P: Deletion mapping of chromosomes 8.10, and 16 in human prostatic carcinoma. Genes Chrom Cancer 3:215-220 (1991).
2. Brothman AR, Maxwell TM, Cui J, Deubler DA, Zhu XL: Chromosomal clues to the development of prostate tumors. Prostate 38:303-312 (1999).
3. Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, Isaacs WB: Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc natl Acad Sci, USA 87:8751-8755 (1990).
4. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH: Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotvping. Cancer Res 56:3091-3102 (1996).
5. Eagle LR, Yin X, Brothman AR, Williams BJ, Atkin NB, Prochownik EV: Mutation of the MX11 gene in prostate cancer. Nature Genet 9:249-255 (1995).
6. Ghadimi BM, Sehroek E, Walker RL, Wangsa D, Jauho A, Meltzer PS, Ried T: Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas. Am J Pathol 154:525-536 (1999).
7. Gibas Z, Becher R, Kawinski E, Horoszewicz J, Sandberg AA: A high-resolution study of chromosome changes in a human prostatic carcinoma cell line (LNCaP). Cancer Genet Cytogenct 11:399-404 (1984).
8. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chaj LS, Kakati S, Ana SK, Sandberg AA: Models for Prostate Cancer, pp 115-132 (Alan R Liss, New York 1980).
9. ISCN: An International System for Human Cytogenetic Nomenclature (Mitelman F. ed) (Karger, Basel 1995).
10. Isaacs WB: Molecular genetics of prostate cancer. Cancer Surv 25:357-379 (1995).
11. Jenkins RB, Qian J, Lieber MM, Bostwick DG: Detection of e-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 57:524-531 (1997).
12. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17:16-23 (1979).
13. Kallioniemi OP, Visakorpi T: Genetic basis and clonal evolution of human prostate cancer. Adv Cancer Res 68:225-255 (1996).
14. Konig JJ, Teubel W, Kamst E, Romijn JC, Schroder FH, Hagemeijer A: Cytogenetic analysis of 39 prostate carcinomas and evaluation of short-term tissue culture techniques. Cancer Genet Cytogenet 101:116-122 (1998).
15. Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature 396:643-649 (1998).
16. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947 (1997).
17. Liyanage M, Coleman A, du Manoir S, Veldman T, McCormack S, Dickson RB, Barlow C, Wynshaw-Boris A, Janz S, Wienberg J, Ferguson-Smith MA, Schrock E, Ried T: Multicolour spectral karyotyping of mouse chromosomes. Nature Genet 14:312-315 (1996).
18. Macville M, Schrock E, Padilla-Nash H, Keck C, Ghadimi BM, Zimonjic D, Popescu N, Ried T: Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by spectral karyotyping. Cancer Res 59:141-150 (1999).
19. Matsuyama H, Pan Y, Skoog L, Tribukait B, Naito K, Ekman P, Lichter P, Bergerheim US: Deletion mapping of chromosome 8p in prostate cancer by fluorescence in situ hybridization. Oncogene 9:3071-3076 (1994).
20. Nupponen NN, Hyytinen ER, Kallioniemi AH, Visakorpi T: Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization. Cancer Genet Cytogenet 101:53-57 (1998a).
21. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T: Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 153:141-148 (1998b).
22. Ohnuki Y, Marnell MM, Babcock MS, Lechner JF, Kaighn ME: Chromosomal analysis of human prostatic adenocarcinoma cell lines. Cancer Res 40:524-534 (1980).
23. Pan Y, Matsuyama H, Wang N, Yoshihiro S, Haggarth L, Li C, Tribukait B, Ekman P, Bergerheim US: Chromosome 16q24 deletion and decreased E-cadherin expression: possible association with metastatic potential in prostate cancer. Prostate 36:31-38 (1998).
24. Prochownik EV, Eagle Grove L, Deubler D, Zhu XL, Stephenson RA, Rohr LR, Yin X, Brothman AR: Commonly occurring loss and mutation of the MXI1 gene in prostate cancer. Genes Chrom Cancer 22:295-304 (1998).
25. Rao PH, Cigudosa JC, Ning Y, Calasanz MJ, Iida S, Tagawa S, Michaeli J, Klein B, Dalla-Favera R, Jhanwar SC, Ried T, Chaganti RS: Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma. Blood 92:1743-1748 (1998).
26. Ried T, Liyanage M, du Manoir S, Heselmeyer K, Auer G, Macville M, Schrock E: Tumor cytogenetics revisited: comparative genomic hybridization and spectral karyotyping. J molec Med 75:801-814 (1997).
27. Sandberg AA: Chromosomal abnormalities and related events in prostate cancer. Hum Pathol 23:368-380 (1992).
28. Schrock E, du Manoir S, Veldman T, Schoell B, Wienberg J, Ferguson-Smith MA, Ning Y, Ledbetter DH, Bar-Am I, Soenksen D, Garini Y, Ried T: Multicolor spectral karyotyping of human chromosomes. Science 273:494-497 (1996).
29. Speicher MR, Gwyn Ballard S, Ward DC: Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nature Genet 12:368-375 (1996).
30. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF: Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21:274-281 (1978).
31. Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, Isaacs WB, Bova GS: Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 58:204-209 (1998).
32. Tribukait B: DNA flow cytometry in carcinoma of the prostate for diagnosis, prognosis and study of tumor biology. Acta oncol 30:187-192 (1991).
33. Van Den Berg C, Guan XY, Von Hoff D, Jenkins R, Bittner M, Griffin C, Kallioniemi O, Visakorpi T, McGill J, Herath J, Epstein J, Sarosdy M, Meltzer P, Trent J: DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications. Clin Cancer Res 1:11-18 (1995).
34. Veldman T, Vignon C, Schrock E, Rowley JD, Ried T: Hidden chromosome abnormalities in haematological malignancies detected by multicolour spectral karyotyping. Nature Genet 15:406-410 (1997).
35. Visakorpi T, Hyytinen E, Kallioniemi A, Isola J, Kallioniemi OP: Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization. Am J Pathol 145:624-630 (1994a).
36. Visakorpi T, Kylmala T, Tainio H, Koivula T, Tammela T, Isola J: High cell proliferation activity determined by DNA flow cytometry predicts poor prognosis after relapse in prostate cancer. Eur J Cancer 1:129-130 (1994b).
37. Visakorpi T, Kallioniemi AH, Syvanen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP: Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 55:342-347 (1995).
38. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW: Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 57:406-441 (1994).